Form 4: ADIAL Pharmaceuticals CFO Vinay Shah Granted 9,000 Stock Options

ADIAL Pharmaceuticals' Chief Financial Officer, Vinay Shah, was granted 9,000 stock options with an exercise price of $0.688, vesting monthly over 36 months starting May 29, 2025.

Summary

• Vinay Shah, the Chief Financial Officer of ADIAL Pharmaceuticals, Inc. (ADIL), was granted 9,000 stock options.
• The stock options have an exercise price of $0.688 per share.
• The options will vest pro rata on a monthly basis over a period of 36 months, commencing on May 29, 2025.
• The expiration date for these stock options is May 28, 2035.
• Following this transaction, Vinay Shah beneficially owns 9,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management incentives with shareholder interests and supports executive retention. It is a routine compensation event.

Positives

• The grant of stock options to a key executive like the CFO aligns management's financial interests with those of shareholders, incentivizing long-term performance.
• The 36-month vesting schedule encourages long-term commitment and retention of the Chief Financial Officer.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, although the impact of 9,000 shares is likely minimal.

Risks

• The value of the granted stock options is directly tied to the future market price of ADIAL Pharmaceuticals' common stock, which is subject to market volatility and company-specific performance.
• Potential future dilution for existing shareholders if these options are exercised, increasing the total number of outstanding shares.

Future Outlook

This document primarily reports an insider equity transaction and does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, beyond the vesting and expiration terms of the options.

Industry Context

The granting of stock options to key executives is a standard practice in the pharmaceutical and biotechnology industries, serving as a common component of executive compensation packages. This practice aims to incentivize long-term performance, align management's interests with shareholder value creation, and retain critical talent within the competitive sector.

Comparison to Industry Standards

• Stock option grants with multi-year vesting schedules are a common and accepted form of executive compensation across various industries, including pharmaceuticals, designed to foster long-term commitment and performance.
• The exercise price being set at the market price on the grant date ($0.688) is a standard industry practice for incentive stock options.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized management performance, balanced against minor potential future dilution from option exercise.
• Employees: May signal stability and standard executive compensation practices within the company.

Next Steps

• The 9,000 stock options granted to Vinay Shah will continue to vest on a monthly basis over the next 36 months.
• Vinay Shah may choose to exercise these options upon vesting, subject to market conditions and his personal financial strategy.

Key Dates

Keywords

ADIAL Pharmaceuticals, ADIL, Stock Options, Form 4, Insider Transaction, Executive Compensation, Vinay Shah, CFO, Equity Grant, Beneficial Ownership